Healthcare / Medical DevicesNasdaqGM
$2.84
-0.20 (-6.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $1.1M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$569M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.3%
↓Gross Margin
54.5%
↑Debt/Equity
1.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+16.5%
FCF CAGR
—
FCF margin
0.5%
FCF / Net income
-0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $206.1M · net income $-15.6M · FCF $1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $206.1M | $206.1M | $180.3M | $156.4M | $162.0M | $159.5M | $114.2M | $93.8M | $76.1M | $51.3M | $39.3M | $34.2M | $36.4M | $39.7M | $36.8M | $33.0M | $23.1M | $18.0M |
| Net Income | $-15.6M | $-15.6M | $-20.9M | $-37.5M | $-42.8M | $-54.4M | $-59.9M | $-71.2M | $-57.6M | $-60.6M | $-62.9M | $-55.9M | $-38.8M | $-43.3M | $-15.9M | $-17.0M | $-16.9M | $-24.1M |
| EBITDA | $-5.5M | $-5.5M | $-10.0M | $-26.3M | $-33.5M | $-45.8M | $-55.2M | $-63.8M | $-53.5M | $-55.7M | $-59.6M | $-59.4M | $-43.1M | $-27.6M | $-16.6M | $-15.0M | $-15.1M | $-23.0M |
| EPS | -0.08 | -0.08 | -0.11 | -0.21 | -0.24 | -0.32 | -0.37 | — | -0.44 | -0.56 | -0.62 | -0.61 | -0.61 | -0.64 | -0.33 | -0.35 | -0.42 | -0.69 |
| Gross Margin | 54.5% | 54.5% | 55.2% | 55.3% | 53.7% | — | — | — | — | — | 43.0% | 31.4% | 41.8% | 43.0% | 43.7% | 36.5% | 41.7% | 30.0% |
| Operating Margin | -4.2% | -4.2% | -7.9% | -16.8% | -21.0% | -30.7% | -51.1% | -70.6% | -72.3% | -112.1% | -156.5% | -178.5% | -122.2% | -71.4% | -47.0% | -48.2% | -69.1% | -132.5% |
| Net Margin | -7.6% | -7.6% | -11.6% | -24.0% | -26.4% | -34.1% | -52.4% | -76.0% | -75.7% | -118.0% | -160.2% | -163.2% | -106.4% | -109.3% | -43.3% | -51.4% | -73.2% | -134.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 1.51 | 1.51 | 1.75 | 1.82 | 1.29 | — | — | — | — | — | — | 0.21 | 0.24 | — | — | — | — | — |
| Current Ratio | 1.63 | 1.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $1.1M | $1.1M | $8.5M | $-47.8M | $-27.6M | $-34.8M | $-43.4M | $-74.4M | $-32.4M | $-52.6M | $-54.1M | — | — | $-27.5M | $-14.0M | $-15.8M | $-16.0M | $-14.7M |
| Returns | ||||||||||||||||||
| ROE | -24.3% | -24.3% | -37.3% | -71.2% | -63.3% | -64.3% | -57.7% | -124.9% | -68.1% | -155.6% | -108.9% | -59.0% | -93.3% | -101.3% | -83.3% | -92.7% | -71.3% | -112.5% |
| Valuation | ||||||||||||||||||
| P/B | 8.43 | 8.43 | 5.52 | 6.71 | 9.87 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 14.3% | 14.3% | 15.3% | -3.5% | — | 39.6% | 21.8% | 23.3% | 48.2% | 30.7% | 14.8% | -6.0% | -8.2% | 7.8% | 11.3% | 43.0% | 28.5% | — |
| EPS Growth | 27.3% | 27.3% | 47.6% | 12.5% | — | 13.5% | — | — | 21.4% | 9.7% | -1.6% | 0.0% | 4.7% | -93.9% | 5.7% | 16.7% | 39.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+123.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.08
Residual
+123.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.